Core Discrete Event Simulation Model for the Evaluation of Health Care Technologies in Major Depressive Disorder

被引:11
|
作者
Vataire, Anne-Lise [1 ]
Aballea, Samuel [1 ]
Antonanzas, Fernando [2 ]
Hakkaart-van Roijen, Leona [3 ]
Lam, Raymond W. [4 ]
McCrone, Paul [5 ]
Persson, Ulf [6 ]
Toumi, Mondher [7 ]
机构
[1] Creat Ceut, F-75008 Paris, France
[2] Univ La Rioja, Logrono, Spain
[3] Erasmus Univ, Rotterdam, Netherlands
[4] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[5] Kings Coll London, London, England
[6] Swedish Inst Hlth Econ, Lund, Sweden
[7] Univ Lyon, Lyon, France
关键词
antidepressants; cost-effectiveness; depression; discrete event simulation; RESIDUAL SYMPTOMS; IMPACT; REMISSION; CITALOPRAM; COSTS; RISK;
D O I
10.1016/j.jval.2013.11.012
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objective: A review of existing economic models in major depressive disorder (MDD) highlighted the need for models with longer time horizons that also account for heterogeneity in treatment pathways between patients. A core discrete event simulation model was developed to estimate health and cost outcomes associated with alternative treatment strategies. Methods: This model simulated short- and long-term clinical events (partial response, remission, relapse, recovery, and recurrence), adverse events, and treatment changes (titration, switch, addition, and discontinuation) over up to 5 years. Several treatment pathways were defined on the basis of fictitious antidepressants with three levels of efficacy, tolerability, and price (low, medium, and high) from first line to third line. The model was populated with input data from the literature for the UK setting. Model outputs include time in different health states, quality-adjusted life-years (QALYs), and costs from National Health Service and societal perspectives. The codes are open source. Results: Predicted costs and QALYs from this model are within the range of results from previous economic evaluations. The largest cost components from the payer perspective were physician visits and hospitalizations. Key parameters driving the predicted costs and QALYs were utility values, effectiveness, and frequency of physician visits. Differences in QALYs and costs between two strategies with different effectiveness increased approximately twofold when the time horizon increased from 1 to 5 years. Conclusion: The discrete event simulation model can provide a more comprehensive evaluation of different therapeutic options in MDD, compared with existing Markov models, and can be used to compare a wide range of health care technologies in various groups of patients with MUD.
引用
收藏
页码:183 / 195
页数:13
相关论文
共 50 条
  • [31] Pharmacokinetic evaluation of vortioxetine for the treatment of major depressive disorder
    Dubovsky, Steven L.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2014, 10 (05) : 759 - 766
  • [32] An empirical comparison of Markov cohort modeling and discrete event simulation in a capacity-constrained health care setting
    L. B. Standfield
    T. A. Comans
    P. A. Scuffham
    The European Journal of Health Economics, 2017, 18 : 33 - 47
  • [33] Can discrete event simulation be of use in modelling major depression?
    Le Lay A.
    Despiegel N.
    François C.
    Duru G.
    Cost Effectiveness and Resource Allocation, 4 (1)
  • [34] Evaluation of the benefits of exercise on cognition in major depressive disorder
    Greer, Tracy L.
    Furman, Jennifer L.
    Trivedi, Madhukar H.
    GENERAL HOSPITAL PSYCHIATRY, 2017, 49 : 19 - 25
  • [35] Discrete event simulation - Helpdesk model in SIMPROCESS
    Kuncova, Martina
    Wasserbauer, Pavel
    21ST EUROPEAN CONFERENCE ON MODELLING AND SIMULATION ECMS 2007: SIMULATIONS IN UNITED EUROPE, 2007, : 105 - +
  • [36] Evaluation of health benefits and harms of the breast cancer screening programme in the Basque Country using discrete event simulation
    Arrospide, Arantzazu
    Rue, Montserrat
    van Ravesteyn, Nicolien T.
    Comas, Merce
    Larranaga, Nerea
    Sarriugarte, Garbine
    Mar, Javier
    BMC CANCER, 2015, 15
  • [37] Performance and cost evaluation of health information systems using micro-costing and discrete-event simulation
    Rejeb, Olfa
    Pilet, Claire
    Hamana, Sabri
    Xie, Xiaolan
    Durand, Thierry
    Aloui, Saber
    Doly, Anne
    Biron, Pierre
    Perrier, Lionel
    Augusto, Vincent
    HEALTH CARE MANAGEMENT SCIENCE, 2018, 21 (02) : 204 - 223
  • [38] Sleep disturbances: Core symptoms of major depressive disorder rather than associated or comorbid disorders
    Mendlewicz, Julien
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2009, 10 (04) : 269 - 275
  • [39] A Primary Care Focus on the Treatment of Patients With Major Depressive Disorder
    Weihs, Karen
    Wert, Jonathan M.
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2011, 342 (04) : 324 - 330
  • [40] Predictors of remission from major depressive disorder in secondary care
    Salvo, Lilian
    Saldivia, Sandra
    Parra, Carlos
    Cifuentes, Manuel
    Bustos, Claudio
    Acevedo, Paola
    Diaz, Marcela
    Ormazabal, Mitza
    Guerra, Ivonne
    Navarrete, Nicol
    Bravo, Veronica
    Castro, Andrea
    REVISTA MEDICA DE CHILE, 2017, 145 (12) : 1514 - 1524